BR112018075281A2 - Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer - Google Patents

Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer Download PDF

Info

Publication number
BR112018075281A2
BR112018075281A2 BR112018075281-9A BR112018075281A BR112018075281A2 BR 112018075281 A2 BR112018075281 A2 BR 112018075281A2 BR 112018075281 A BR112018075281 A BR 112018075281A BR 112018075281 A2 BR112018075281 A2 BR 112018075281A2
Authority
BR
Brazil
Prior art keywords
sequence
fact
virus
protein
peptide
Prior art date
Application number
BR112018075281-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Luo Tianci
Molina Rene
CASTILLE Gabriel
Original Assignee
Wellstat Immuno Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Immuno Therapeutics, Llc filed Critical Wellstat Immuno Therapeutics, Llc
Publication of BR112018075281A2 publication Critical patent/BR112018075281A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018075281-9A 2017-05-10 2018-05-10 Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer BR112018075281A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
US62/504,120 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112018075281A2 true BR112018075281A2 (pt) 2020-02-11

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075281-9A BR112018075281A2 (pt) 2017-05-10 2018-05-10 Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer

Country Status (13)

Country Link
US (2) US11274141B2 (https=)
EP (1) EP3621635A4 (https=)
JP (1) JP7161940B2 (https=)
KR (3) KR20250118857A (https=)
CN (3) CN121343934A (https=)
AU (1) AU2018265258B2 (https=)
BR (1) BR112018075281A2 (https=)
CA (1) CA3026892A1 (https=)
IL (1) IL263979B2 (https=)
MX (1) MX2018015599A (https=)
NZ (1) NZ748798A (https=)
WO (1) WO2018209052A1 (https=)
ZA (1) ZA201808040B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112759654A (zh) * 2019-11-06 2021-05-07 深圳普菲科生命科技有限公司 一种病毒囊膜蛋白装配系统及其方法和应用
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
US20240067936A1 (en) * 2021-02-26 2024-02-29 Sillajen, Inc. Oncolytic virus and uses thereof
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR20240003051A (ko) * 2022-06-29 2024-01-08 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
KR20240035360A (ko) * 2022-09-07 2024-03-15 신라젠(주) 항암 바이러스의 신규 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
US6475756B1 (en) * 1997-11-21 2002-11-05 Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) Development of viruses resistant to inactivation by the human complement system
JP4544497B2 (ja) 1997-12-22 2010-09-15 ユニバーシティ オブ テネシー リサーチ ファウンデーション 異種融合タンパク質を有する組変えラブドウイルス
NZ507063A (en) * 1998-04-02 2003-11-28 Rigel Pharmaceuticals Inc Self-dimerising peptides causing the formation of compact structures
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
CA2574282A1 (en) 2004-07-21 2006-03-02 Dana-Farber Cancer Institute, Inc. Lentiviral vectors and uses thereof
JP5050198B2 (ja) * 2006-09-05 2012-10-17 国立大学法人大阪大学 ヒト補体制御因子発現遺伝子およびその利用
WO2008118258A2 (en) * 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
US20140206850A1 (en) 2011-04-29 2014-07-24 Keygene N.V. Glyphosate resistance enhancement
EP2704744B1 (en) 2011-05-05 2019-04-24 Wellstat ImmunoTherapeutics, LLC Complement factor b analogs and their uses
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
DK3143134T3 (da) * 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
WO2017197525A1 (en) 2016-05-19 2017-11-23 Evgin Laura Pseudotyped oncolytic rhabdoviruses and their use in combination therapy

Also Published As

Publication number Publication date
IL263979A (en) 2019-02-28
EP3621635A4 (en) 2021-02-24
CA3026892A1 (en) 2018-11-15
JP7161940B2 (ja) 2022-10-27
CN121343935A (zh) 2026-01-16
IL263979B2 (en) 2023-09-01
JP2020519230A (ja) 2020-07-02
EP3621635A1 (en) 2020-03-18
KR20250118857A (ko) 2025-08-06
CN121343934A (zh) 2026-01-16
RU2018146446A3 (https=) 2021-09-10
NZ748798A (en) 2026-03-27
ZA201808040B (en) 2019-09-25
KR20240073085A (ko) 2024-05-24
CN109414483B (zh) 2025-10-24
US20190194292A1 (en) 2019-06-27
MX2018015599A (es) 2019-05-16
IL263979B1 (en) 2023-05-01
CN109414483A (zh) 2019-03-01
US11274141B2 (en) 2022-03-15
KR102839445B1 (ko) 2025-07-28
WO2018209052A1 (en) 2018-11-15
KR20200005721A (ko) 2020-01-16
RU2018146446A (ru) 2021-06-10
KR102662049B1 (ko) 2024-05-23
AU2018265258A1 (en) 2019-01-17
US20220169701A1 (en) 2022-06-02
AU2018265258B2 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
BR112018075281A2 (pt) Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer
ES2231494T3 (es) Compuestos antiinflamatorios y sus usos.
CN109475613A (zh) 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达
Richard-Fiardo et al. Evaluation of tetrafunctional block copolymers as synthetic vectors for lung gene transfer
US7772367B2 (en) C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
US9808505B2 (en) Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)
US20140271564A1 (en) Vesicular stomatitis viruses containing a maraba virus glycoprotein polypeptide
AU2017205538B2 (en) A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor
CN108440673A (zh) Fc融合蛋白PD1/FGFR1及其应用
US20250064873A1 (en) TNFSF-L Fusion Proteins and Uses Thereof
ES2390763T3 (es) Fragmentos peptídicos del factor HARP que inhiben la angiogénesis
ES2618899T3 (es) Zimógeno de proteína C y procedimientos de utilización del mismo para prevenir las metástasis del cáncer
JP2003501362A (ja) 脈管形成インヒビターとしてのｃ−ｃａｍ
ES2751361T3 (es) Factor VIII de la coagulación con inmunogenicidad reducida
US20220251167A1 (en) T-Cell Receptor for Treating Fibrolamellar Hepatocellular Carcinoma
CN116769011B (zh) 一种视网膜母细胞瘤蛋白突变体及其制备方法和应用
HK40104197A (zh) Tnfsf-l融合蛋白及其用途
CA3245759A1 (en) NEW USE OF GENETICALLY MODIFIED MEASLES ONCOLYTIC VIRUS
US20010036929A1 (en) Xrcc3 is required for assembly of Rad51-complexes in vivo
CN119746032A (zh) Anxa2在制备药物性肝损伤药物中的应用
WO2025212872A1 (en) T-bet induces tumor cell apoptosis and its utility in cancer therapy
TW202604543A (zh) 於實體腫瘤的ｐ２１工程化單核球及放射療法
Mediche ADENOVIRAL VECTORS: MOLECULAR BASIC OF IMMUNE RESPONSES
Meliani et al. 595. Enhanced Liver Transduction and Efficient Protection from Pre-Existing Neutralizing Antibodies with Exosome-Associated AAV8 Vectors
JP2001505205A (ja) 細胞を形質導入するための改善された方法

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: PHARMA CINQ, LLC (US)